Olatorepatide
HS-20094 · Hansoh / Regeneron
Dual-biased GLP-1/GIP agonist with Phase 3 LIGHTEN primary results presented at EASD 2026; global development and regulatory outcomes remain ahead.
Selected study results
LIGHTEN Phase 3 primary results · EASD 2026Mean body-weight change from baseline at week 48Body weight decreased 19.3% · 48 weeks · Phase 3
Mean body-weight change from baseline at week 48 · 48 weeks
Study focus: Weight management
Chinese adults with overweight or obesity · 15 mg once weekly vs placebo · Trial N=604 · Efficacy estimand; sponsor-reported EASD 2026 LBA 27 results. Results & methods ↗
- Other doses · efficacy estimandAt week 48, mean body-weight change was −12.5% with 5 mg, −17.5% with 10 mg, and −19.3% with 15 mg, versus −2.7% with placebo. Follow-up source ↗
- Treatment-regimen estimandAt week 48, mean body-weight change was −11.8% with 5 mg, −17.0% with 10 mg, and −18.7% with 15 mg, versus −2.5% with placebo. Follow-up source ↗
- Study completion90.1% of participants completed the 48-week treatment period. Follow-up source ↗
Conference abstract results reported in a sponsor-issued release; peer-reviewed full publication not located. Study enrolled adults in China.
Each graphic shows results within one study. Alternate analyses and follow-up from that study are labeled together. Study averages are not individual predictions or cross-trial comparisons.
Mechanism at a glance
Obesity stage by formulation
Latest: LIGHTEN Phase 3 primary results presented as EASD 2026 Late-Breaking Abstract 27.
Next: Peer-reviewed LIGHTEN results and global RISE-1 initiation; RISE-1 is registered, not yet recruiting.
Clinical study records
Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.
Obesity and weight-management studies
Phase 3 studies2 records
LIGHTEN (HS-20094-301)
Weight managementRandomized, double-blind, placebo-controlled Phase 3 study in 604 Chinese adults with overweight or obesity; once-weekly 5, 10, or 15 mg or placebo for 48 weeks.
RISE-1 · global
Weight managementRegistered global Phase 3, estimated 3,000 participants and a week-72 weight endpoint; not yet recruiting, with an estimated November 18, 2026 start. Distinct from China LIGHTEN.
